Who Core Delta Is For

You are a fit if:

You are not a fit if:

You are in a live financing conversation — a cap being proposed, a term sheet in hand, or plan to have a round opening in the next six months.
Your device is on an FDA pathway: Class I, Class II under 510(k)/Exempt or De Novo, or Class III under PMA.
You are anywhere from pathway definition through a priced Series A — the stretch where your number is most contested, whether it is a Seed cap or a Series A pre-money.
You are pricing a Series A on its economics — setting the anchor yourself, or testing a lead's term sheet against your own number.
You would rather find the hole in your own numbers than have an investor find it.

You are not a fit if:

You are pre-prototype with no pathway view. The analysis would tell you things you cannot act on.
You have under four months of runway. You need a bridge, not a positioning exercise.
You are CE-mark first with FDA deferred. Our benchmarks and base rates are FDA-derived and will not price an MDR milestone honestly.
You want a number that flatters a round you have already planned.
You need someone to run your raise and open doors. That is not the service, and an occasional unpaid introduction is not a substitute for it.

If you are building outside the United States:

An FDA device is a US asset, wherever you built it.

A company in Tel Aviv, Dublin, Eindhoven or Toronto pursuing a 510(k) is building an asset that will eventually be re-rated against what US Class II companies at that stage are worth. But the round is usually priced by local investors against local comparables.

Part of that discount is earned. Distance from the US market is real execution risk — clinical sites, reimbursement, commercial build, and probably a US restructuring somewhere ahead. Part of it is habit.

Separating the two is the work. Our benchmarks are keyed to FDA class and pathway, not to geography, so the analysis applies wherever you are incorporated.

If you are on the other side of the table:

If you are building outside the United States:

Independent reads for angel groups and syndicates.

The same arithmetic runs from the investor’s chair. If your group is evaluating an early device deal and wants an independent read on the risk profile and whether the cap or pre-money clears, that is a fixed-fee engagement per asset.

Ask about investor-side work

Who Core Delta Is For — And Who It Is Not

The qualifier is not attitude. It is timing.

You are a fit if:

You are not a fit if:

You are not a fit if:

You are not a fit if:

You are not a fit if:

You are not a fit if:

If you are building outside the United States:

If you are building outside the United States:

If you are building outside the United States:

If you are on the other side of the table:

If you are building outside the United States:

If you are building outside the United States:

Who Core Delta Is For — And Who It Is Not

The qualifier is not attitude. It is timing.

You are a fit if:

You are not a fit if:

You are not a fit if:

You are not a fit if:

You are not a fit if:

You are not a fit if:

If you are building outside the United States:

If you are building outside the United States:

If you are building outside the United States:

If you are on the other side of the table:

If you are building outside the United States:

If you are building outside the United States:

This website uses cookies.